| Filed On | Filing |
|---|---|
| 07 Jan 2025 |
8-K/A: Financial Statements and Exhibits
We have audited the financial statements of Opus Genetics, Inc. (the Company), which comprise the balance sheet as of December 31, 2023, and the related statements of operations and comprehensive loss, changes in convertible preferred st... |
| 07 Jun 2021 |
8-K/A: Entry into a Material Definitive Agreement; Other Events
PURCHASE AGREEMENT (this “Agreement”), dated as of June 4, 2021, by and among OCUPHIRE PHARMA, INC., a Delaware corporation (the “Company”), and the investors identified on Schedule I hereto (each, an “Investor” and collectively, the “In... |
| 30 Dec 2020 |
8-K/A: Financial Statements and Exhibits
Ocuphire Pharma, Inc. (Ocuphire or the Company) was incorporated as a C-corporation in the state of Delaware on February 21, 2018. On April 9, 2018, Ocularis Pharma, LLC, a Delaware limited liability company (LLC), and Ocularis Pharma, I... |
| 02 Mar 2009 |
8-K/A: Changes in Registrant's Certifying Accountant
We are the former independent registered public accounting firm for Rexahn Pharmaceuticals, (the "Company"). We have read the Company's disclosure set forth in Item 4.01 "Changes in Registrant's Certifying Accountant" of the Company's Cu... |
Loading...